CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-11-19): Bayer's Nexavar gets U.S. FDA nod for liver cancer

Regulatory

Bayer's Nexavar gets U.S. FDA nod for liver cancer

Last Updated: 2007-11-19 14:23:41 -0400 (Reuters Health)

FRANKFURT (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Nexavar (sorafenib) to treat liver cancer, Bayer said on Monday.

Bayer already got approval from the European Commission to sell Nexavar for liver cancer treatment last month.

Nexavar is already approved in Europe and the United States for kidney cancer.

Bayer is developing the drug together with its U.S. partner Onyx Pharmaceuticals.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.